基于超灵敏数字免疫分析的血浆生物标志物诊断模型作为中国人群阿尔茨海默病筛查策略的开发
研究纳入159例AD、148例aMCI和121例认知正常对照,用Simoa平台检测血浆Aβ42、Aβ40、Aβ42/Aβ40、t-tau、p-tau181和NFL,建立综合与简化诊断模型。简化模型联合血浆p-tau181、Aβ42和临床特征鉴别AD与对照的AUC为93.3%、灵敏度78.6%、特异度94.2%,接近综合模型(AUC 95.1%、灵敏度85.5%、特异度94.2%)。
要点
- 血浆p-tau181在全部血液标志物中识别认知 impairment 患者的潜力最大。
- 简化模型(p-tau181+Aβ42+临床特征)鉴别AD与对照AUC达93.3%。
- 简化模型对早发型和晚发型AD/对照的AUC分别为95.9%和94.0%。
核心结论
- 基于血浆生物标志物建立的中国人群AD诊断模型中,简化模型可为临床和社区大规模筛查提供可及且实用的途径,尤其适合发展中国家。
研究设计与样本
- 研究纳入159例AD、148例aMCI和121例认知正常对照,来自2个队列。
- 使用超灵敏单分子阵列(Simoa)平台定量血浆Aβ42、Aβ40、Aβ42/Aβ40、t-tau、p-tau181和NFL。
- 基于血浆生物标志物谱和临床特征建立综合与简化诊断模型。
主要发现
- 全部血液标志物中,p-tau181识别认知 impairment 患者的潜力最大。
- 简化模型鉴别AD与对照的AUC为93.3%、灵敏度78.6%、特异度94.2%。
- 综合模型(5种血浆标志物+临床特征)鉴别AD与对照的AUC为95.1%、灵敏度85.5%、特异度94.2%。
- 简化模型对早发型AD/对照的AUC为95.9%,对晚发型AD/对照的AUC为94.0%。
关键数值与推荐
- 简化模型联合血浆p-tau181、Aβ42和临床特征,鉴别AD与对照AUC 93.3%、灵敏度78.6%、特异度94.2%。
- 综合模型包括5种血浆生物标志物和临床特征,鉴别AD与对照AUC 95.1%、灵敏度85.5%、特异度94.2%。
- 简化模型对早发型AD/对照AUC 95.9%,对晚发型AD/对照AUC 94.0%。
临床怎么用
- 简化诊断模型基于血浆p-tau181、Aβ42和临床特征,可作为中国人群AD临床和社区大规模筛查的可及实用方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The ultrasensitive detection of blood-based biomarkers such as amyloid β (Aβ), tau, and neurofilament light (NFL) has drawn much attention in Alzheimer disease (AD) diagnosis. However, few studies have been conducted in the Chinese population. This study aimed to evaluate the ability of plasma biomarker diagnostic models for AD in the Chinese population based on a novel digital immunoassay technology. METHODS: 159 patients with AD, 148 patients with amnestic mild cognitive impairment (aMCI), and 121 cognitively normal control participants were recruited from 2 cohorts. The concentrations of plasma Aβ42, Aβ40, Aβ42/Aβ40, total tau (t-tau), phosphorylated tau 181 (p-tau 181), and NFL were quantified using an ultrasensitive single molecule array (Simoa) platform. Comprehensive and simplified diagnostic models were established based on the plasma biomarker profile and clinical characteristics. RESULTS: Among all blood biomarkers, p-tau181 had the greatest potential for identifying patients with cognitive impairment. The simplified diagnostic model, which combined plasma p-tau181, Aβ42, and clinical features, achieved 93.3% area under the curve (AUC), 78.6% sensitivity, and 94.2% specificity for distinguishing AD from control participants, indicating a diagnostic ability approaching that of the comprehensive diagnostic model including 5 plasma biomarkers and clinical characteristics (95.1% AUC, 85.5% sensitivity, 94.2% specificity). Moreover, the simplified model reached 95.9% AUC and 94.0% AUC for early- and late-onset AD/control participants, respectively. CONCLUSIONS: We established AD diagnostic models using plasma biomarkers for Chinese participants. These findings suggest the simplified diagnostic model provides an accessible and practical way for large-scale screening in the clinic and community, especially in developing countries.
引用
- Wu X, Xiao Z, Yi J, et al. Development of a Plasma Biomarker Diagnostic Model Incorporating Ultrasensitive Digital Immunoassay as a Screening Strategy for Alzheimer Disease in a Chinese Population. Clin Chem. 2021. PMID: 34662373. doi:10.1093/clinchem/hvab192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。